ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,00%
Bitcoin
60.899,56
0,17%
Brent Oil
82,585
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) Notícias

ARVN

Arvinas (ARVN)

Arvinas Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ARVN
DataHoraFonteTítuloCódigoCompanhia
09/05/202417:42GlobeNewswire Inc.Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNASDAQ:ARVNArvinas Inc
07/05/202417:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARVNArvinas Inc
07/05/202408:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
07/05/202408:00GlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
02/05/202408:00GlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
24/04/202417:30GlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
11/04/202408:00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
18/03/202417:40GlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
04/03/202409:00GlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
27/02/202420:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
27/02/202418:46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
27/02/202409:00GlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
20/02/202418:05GlobeNewswire Inc.Arvinas Announces Chief Financial Officer TransitionNASDAQ:ARVNArvinas Inc
20/02/202409:00GlobeNewswire Inc.Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseNASDAQ:ARVNArvinas Inc
14/02/202410:00GlobeNewswire Inc.Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast CancerNASDAQ:ARVNArvinas Inc
13/02/202422:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARVNArvinas Inc
06/02/202408:45GlobeNewswire Inc.Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:ARVNArvinas Inc
01/02/202418:30GlobeNewswire Inc.Arvinas to Present at 6th Annual Guggenheim Biotechnology ConferenceNASDAQ:ARVNArvinas Inc
16/01/202419:01GlobeNewswire Inc.Arvinas Appoints Jared Freedberg as General CounselNASDAQ:ARVNArvinas Inc
16/01/202418:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARVNArvinas Inc
08/12/202311:16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ARVNArvinas Inc
06/12/202300:52GlobeNewswire Inc.Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
05/12/202315:33GlobeNewswire Inc.Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
28/11/202319:05GlobeNewswire Inc.Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer SymposiumNASDAQ:ARVNArvinas Inc
27/11/202309:00GlobeNewswire Inc.Arvinas Announces Oversubscribed $350 Million Private PlacementNASDAQ:ARVNArvinas Inc
07/11/202309:00GlobeNewswire Inc.Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
22/10/202308:00GlobeNewswire Inc.Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPCNASDAQ:ARVNArvinas Inc
18/10/202308:00GlobeNewswire Inc.Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact DayNASDAQ:ARVNArvinas Inc
15/10/202319:07GlobeNewswire Inc.Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023NASDAQ:ARVNArvinas Inc
15/10/202319:05GlobeNewswire Inc.Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023NASDAQ:ARVNArvinas Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ARVN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
YDUQ3
ESTACIO PART ON
BOV
UNIP6
UNIPAR PNB
BOV
COGN3
COGNA ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados